Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity

Steensma, David P.; List, Alan F.
May 2005
Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p691
Academic Journal
The myelodysplastic syndromes (MDS) are associated with a diverse set of acquired somatic genetic abnormalities. Bone marrow Karyotyping provides important diagnostic and prognostic information and should be attempted in all patients who are suspected of having MDS. Fluorescent in situ hybridization (FISH) studies on blood or marrow may also be valuable in selected cases, such as patients who may have 5q-syndrome or those who have undergone hematopoietic stem cell transplantation. The MDS-associated cytogenetic abnormalities that have been defined by karyotyping and FISH studies have already contributed substantially to our current understanding of the biology of malignant myeloid disorders, but the pathobiological meaning of common, recurrent chromosomal lesions such as del(5q), del(20q), and monosomy 7 is still unknown. The great diversity of the cytogenetic findings described in MDS highlights the molecular heterogeneity of this cluster of diseases. We review the common and pathophysiologically interesting genetic abnormalities associated with MDS, focusing on the clinical utility of conventional cytogenetic assays and selected FISH studies, in addition, we discuss a series of well-defined MDS-associated point mutations and outline the potential for further Insights from newer techniques such as global gene expression profiling and array-based comparative genomic hybridization.


Related Articles

  • Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry. Donadieu, J.; Michel, G.; Merlin, E.; Bordigoni, P.; Monteux, B.; Beaupain, B.; Leverger, G.; Laporte, J. P.; Hermine, O.; Buzyn, A.; Bertrand, Y.; Casanova, J. L.; Leblanc, T.; Gluckman, E.; Fischer, A.; Stephan, J. L. // Bone Marrow Transplantation;Nov2005, Vol. 36 Issue 9, p787 

    Summary:Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Among 71 SDS patients included in the French Severe Chronic Neutropenia Registry, 10 received HSCT between 1987 and 2004 in five institutions. The...

  • Deregulation of microRNAs in myelodysplastic syndrome. Rhyasen, G W; Starczynowski, D T // Leukemia (08876924);Jan2012, Vol. 26 Issue 1, p13 

    Myelodysplastic syndromes (MDSs) consist of a family of hematopoietic stem cell (HSC) disorders characterized by ineffective differentiation of hematopoietic progenitors, bone marrow dysplasia, genetic instability and a propensity to develop acute myeloid leukemia. The development of MDS is...

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. de Lima, M.; Champlin, R. E.; Thall, P. F.; Wang, X.; Martin, T. G.; Cook, J. D.; McCormick, G.; Qazilbash, M.; Kebriaei, P.; Couriel, D.; Shpall, E. J.; Khouri, I.; Anderlini, P.; Hosing, C.; Chan, K. W.; Andersson, B. S.; Patah, P. A.; Caldera, Z.; Jabbour, E.; Giralt, S. // Leukemia (08876924);Feb2008, Vol. 22 Issue 2, p258 

    We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III–IV...

  • The Myelodysplastic Syndromes: Diagnosis and Treatment. Steensma, David P.; Bennett, John M. // Mayo Clinic Proceedings;Jan2006, Vol. 81 Issue 1, p104 

    The myelodysplastic syndromes (MDS5) are common, acquired, clinically challenging hematologic conditions that are characterized by bone marrow failure and a risk of progression to acute leukemia. These disorders can arise de novo, especially in elderly patients or, less often, as a consequence...

  • Hitting the reset button for immune tolerance. Kirk, Allan D. // Nature Medicine;Jan2001, Vol. 7 Issue 1, p24 

    Cites a study conducted by researchers C.C. Anderson and P. Matzinger addressing the issue of microchimerism, a phenomenon in which donor hematopoietic cells migrate from the transplanted organs and establish residence in other parts of the host's body. Possibility of tolerance induction while...

  • Gently does it. Cohen, Philip // New Scientist;5/4/2002, Vol. 174 Issue 2341, p21 

    Focuses on the strategies developed by surgeons to prevent rejection in organ transplants in California. Use of antibody therapy and irradiation to kill aggressive immune cells of the recipient; Infusion of hematopoietic stems cells from the donor; Temporary transplant of cells from the donor...

  • Management strategies for the hard-to-mobilize patient. Stiff, Patrick J. // Bone Marrow Transplantation;5/1/99 Supplement 2, Vol. 23, pS29 

    Delayed hematopoietic engraftment, particularly of platelets, is seen in 5–35% of patients undergoing high-dose chemotherapy with autologous stem cell transplantation. Studies indicate that delayed engraftment is related to low CD34+ cell dose, and that risk factors for poor mobilization...

  • Unrelated hematopoietic stem cell donors as research subjects. King, R. J.; Confer, D. L.; Greinix, H. T.; Halter, J.; Horowitz, M.; Schmidt, A. H.; Costeas, P.; Shaw, B.; Egeland, T. // Bone Marrow Transplantation;Jan2011, Vol. 46 Issue 1, p10 

    Requests for participation of unrelated stem cell donors in research transplant protocols are becoming more frequent. World Marrow Donor Association calls on donor registries to participate in research activities. Here, we discuss various implications of research participation and make some...

  • Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Strahm, B.; Locatelli, F.; Bader, P.; Ehlert, K.; Kremens, B.; Zintl, F.; Führer, M.; Stachel, D.; Sykora, K.-W.; Sedlacek, P.; Baumann, I.; Niemeyer, C. M. // Bone Marrow Transplantation;Aug2007, Vol. 40 Issue 4, p329 

    Myelodysplastic syndromes (MDS) are a heterogenous group of acquired hematopoietic stem cell disorders. Refractory cytopenia (RC) is the most common subtype of childhood MDS and hematopoietic stem cell transplantation (HSCT) is the only curative treatment. HSCT following a myeloablative...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics